title: Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
abstract: In 27 patients randomized to receive commercial trivalent influenza vaccine (TIV) containing 15 microg of the hemagglutinin (HA) of influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 microg of each HA, reactogenicity was minor. Among patients with similar prevaccination titers, 40% given 45 microg and 60% given 135 microg of rHAO developed an increase in influenza A/H3 neutralizing antibody levels; there were no increases in 4 given TIV. For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135- microg vaccine.
authors.affiliation: Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. asafdar@mdanderson.org
authors.forename: Amar
authors.initials: A
authors.lastname: Safdar
authors.forename: M Alma
authors.initials: MA
authors.lastname: Rodriguez
authors.forename: Luis E
authors.initials: LE
authors.lastname: Fayad
authors.forename: Gilhen H
authors.initials: GH
authors.lastname: Rodriguez
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
authors.forename: Michael
authors.initials: M
authors.lastname: Wang
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Romaguera
authors.forename: Andre H
authors.initials: AH
authors.lastname: Goy
authors.forename: Fredrick B
authors.initials: FB
authors.lastname: Hagemeister
authors.forename: Peter
authors.initials: P
authors.lastname: McLaughlin
authors.forename: Gerald P
authors.initials: GP
authors.lastname: Bodey
authors.forename: Larry W
authors.initials: LW
authors.lastname: Kwak
authors.forename: Issam I
authors.initials: II
authors.lastname: Raad
authors.forename: Robert B
authors.initials: RB
authors.lastname: Couch
mesh_terms: D000914:Antibodies, Viral / Q000097:blood; D016367:Baculoviridae / Q000235:genetics; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D005260:Female; D006389:Hemagglutinins, Viral / Q000235:genetics / Q000276:immunology; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology; D009981:Influenza B virus / Q000276:immunology; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000276:immunology*; D016393:Lymphoma, B-Cell / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D007252:Influenza Vaccines; D014614:Vaccines, Synthetic; D014764:Viral Proteins; C458881:hemagglutinin fusogenic peptide, influenza virus